JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:715-718, doi:10.1016/j.jacc.2005.08.075 (Published online 6 February 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Puma, J. A.
Right arrow Articles by Tcheng, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Puma, J. A.
Right arrow Articles by Tcheng, J. E.

Clinical Characteristics Predict Benefits From Eptifibatide Therapy During Coronary Stenting

Insights From the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) Trial

Joseph A. Puma, DO, FACC*,*, Lesan T. Banko, MD*, Karen S. Pieper, MS{dagger}, Terrence J. Sacchi, MD, FACC*, J. Conor O’Shea, MD{dagger}, Jean Pierre Dery, MD{dagger} and James E. Tcheng, MD, FACC{dagger}

* New York Methodist Hospital-Cornell Heart Center, Brooklyn New York
{dagger} Duke Clinical Research Institute, Durham, North Carolina


Figure 1
View larger version (30K):

[in a new window]
  		Figure 1 Flow of patients.

 

Figure 2
View larger version (21K):

[in a new window]
  		Figure 2 Survival from death or myocardial infarction to 12 months.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.